The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population
|
|
- Julius Andrews
- 6 years ago
- Views:
Transcription
1 Accepted: 6 March 2017 DOI: /cyt ORIGINAL ARTICLE The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population G. Ramos Rivera a S. N. Khader a S. Lajara K. Schlesinger D. Y. Goldstein R. C. Naeem M. J. Suhrland A. S. Fox Pathology Department, Montefiore Medical Center, Bronx, NY, USA Correspondence Gloria Ramos Rivera, Montefiore Medical Center, Bronx, NY, USA. s: Gloria.ramosriv@gmail.com and gramosr@montefiore.org Objective: Persistent infection with oncogenic high risk HPV (hrhpv) types causes virtually all cases of cervical cancer. HPV 16 and 18 have been targeted for individual genotyping and vaccination because of their presence in 71% of invasive cervical cancers worldwide. Montefiore Medical Center, Bronx, New York serves a population known for ethnic and racial diversity. Given this diversity it is possible that HPV genotypes not individually detected by current testing are causing significant disease. Methods: We conducted a retrospective analysis of liquid based cervicovaginal cytology and Cobas HPV results reported between October 5, 2015 and March 30, This included samples from patients aged (average age 42), with racial distribution including: African-American 32.4%, Other (includes denied, unknown, mixed, Hispanic) 52.1%, Caucasian 14.5%, Asian 0.7%, American Indian/Alaskan Native 0.3%. In all, samples (72.9%) were submitted for clinically requested COBAS 4800 HPV testing, which separately reports HPV 16, 18 and a pool of 12 other hrhpv. Results: A total of 3180 (21.5%) tested hrhpv positive. The percentage of patients with cytologic diagnosis of HSIL (high-grade squamous intraepithelial lesion) that were positive only for HPV 16 was 19.4% vs 1.8% for all cytologic diagnoses. However, only one of the HSIL cases was HPV 18 positive along with other hrhpv (OHR). Surprisingly, a majority (64.5%) was positive for only OHR. Conclusions: Further evaluation is needed to determine if this pool of other hrhpv includes individual genotypes that in our population carry a higher risk of persistence and progression to cancer. KEYWORDS HPV, Papanicolaou test, papillomaviridae, uterine cervical neoplasms 1 INTRODUCTION Among the several hrhpv genotypes associated with the development of cervical cancer, HPV 16 and 18 have been shown to be of a These authors contributed equally to this work. primary importance. In two studies, which included a meta-analysis of 1 million women, HPV16 and 18 were the most common hrhpv types detected in patients with both normal and abnormal cytological findings. 1,2 A prospective study has shown a significantly higher cumulative incidence of HSIL in women infected with HPV 16 and/ or Retrospective analyses of cervical cancer biopsies showed Cytopathology. 2017;28: wileyonlinelibrary.com/journal/cyt 2017 John Wiley & Sons Ltd 413
2 414 RAMOS RIVERA ET AL. that HPV 16 and 18 were associated with up to 70% of invasive cancer cases 2 and that HPV 16 was associated with 52.4% of invasive cancer cases. 4 As a result of the prevalence and increased risk of progression to cancer, HPV 16 and 18 were the first genotypes to be targeted by HPV vaccines, Cervarix (GlaxoSmithKline, Brentford, London, UK) and Gardasil (Merck & Co, Kenilworth, NJ, USA), the latter also covering the low-risk HPV types 6 and 11, the aetiologic agents of warts and mucosal papillomatous lesions. In terms of detection, HPV 16 and 18 were also the first to be separately identified in a clinical assay for hrhpv. The Cobas HPV test (Roche Diagnostics, Basel, Switzerland) approved by the Food and Drug Administration (FDA) in 2011, provides individual detection of HPV 16 and HPV 18 from a pool of 12 other hrhpv types. 5 HPV 16 and 18 genotype testing are now incorporated into current American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines for cervical cancer screening. 6,7 While HPV types 16 and 18 have already been a primary clinical concern in HPV testing for some time, ever-evolving guidelines and advancing diagnostic technologies are constantly adding to our knowledge of HPV leading to an understanding broader than simply HPV 16 and 18 alone. Several studies have demonstrated regional and population differences in the distribution of hrhpv genotypes. A study in Ghana found that the most common hrhpv genotypes were HPV 18, 59 and In a study of Southeast Asian women, only one patient tested positive for HPV 16, and the most common hrhpv genotypes were HPV 51, 52, 56, and At Mount Sinai Hospital, New York, HPV 59, 16 and 51 were the most common hrhpv types in women with abnormal cervical cytology. 10 Recognition and understanding of regional variation are important to ensure appropriate molecular detection. Although the latest FDA approved vaccine, Gardasil 9, includes additional hrhpv types: 31, 33, 45, 52 and 58, in addition to 6, 11, 16 and 18, it does not cover 51, 56, or Montefiore Medical Center (MMC), Bronx, New York, serves a population of over 1.4 million individuals. These patients are some of the most underserved in the City of New York as well as in the entire region. 12 The Bronx is known for its ethnic and racial diversity; almost one-third of its residents are immigrants, and over 110 languages are spoken by MMC patients. Bronx census data from 2015 reveals race distribution as, 45.4% White, 43.4% African Americans, 4.5% Asian, 2.9% American Indian and Alaska native, 0.4% Native Hawaiian/Pacific Islander and 3.4% others. 12 It is important to note that 55.1% of the population identified as Hispanics and are distributed among other race categories, whereas 10.1% identified as only White (not Hispanic or latino). 12 In 2015, 4% (1678/42081) of the Pap tests performed at MMC were diagnosed as low-grade squamous intraepithelial lesions (LSIL), and 0.6% (234/42081) were diagnosed as HSIL, indicating a significantly higher risk of developing cervical cancer, when compared with the overall United States population. Based on the Laboratory Percentile-Reporting Rate statistical records from the College of American Pathologists (CAP), our rates for LSIL falls between the 75th and 90th percentile and HSIL is at the 75th percentile. 13 In recognition of the population diversity and increased risk of disease, part of the Pap quality control programme involves senior cytotechnologist rescreening of all negative Paps from patients with a high-risk history (history of abnormal Paps or gynecological histological abnormalities, patients with multiple sex partners, history of sexually transmitted infections or history consistent with high-risk sexual behaviour) This high-risk group comprises 20% of all Paps evaluated. In October 2015, MMC Division of Cytology transitioned their testing platform from Hybrid Capture II (HCII) hrhpv test (Digene Corporation, Gaithersburg, MD, USA) to the Cobas HPV test, to separately identify the presence of hrhpv 16 and 18 types in addition to the other 12 types. This new system at MMC allowed for the first time to consider and examine whether the diverse population served by MMC in the Bronx might present with different distributions of high-risk viral genotypes. Additionally, utilising the Cobas assay allowed for a direct comparison of data presented in the ATHENA study, 14 with its more homogenous populations, to the broad population diversity served by our medical centre. The ATHENA study, a large clinical trial to assess the ability of advanced HPV assays to triage women with abnormal findings on cytopathological examination, had an ancillary objective of looking at the ability of advanced HPV assays being utilised as primary firstline test for cervical cancer screening. 14 ATHENA prospectively analysed data from patients from 61 clinical centres across the United States in which the Cobas HPV test was performed and correlated with cytology and subsequent histology METHODS A retrospective collection of cytology results, along with the hrhpv results were retrieved and analysed on female patients of all ages seen from 5 October 2015 through to 30 March Data collection was performed by querying the in-house pathology information system (SoftPathologyDx ) for all patients having complete data regarding Pap testing. Patient s cytology cases are linked to histology cases by the patient s medical record number in the electronic medical record system. In the case of all HSILs cases diagnosed on Pap tests, an additional query was performed to find the histological diagnosis, if available. Sample collection and cytopathological preparations were performed utilising liquid-based cytology (SurePathâ Pap Test) and a slide preparation system according to manufacturers recommendations. Slides produced underwent screening, quality control rescreening as needed, and cytopathologist review as needed. Negative Pap test cytology diagnoses are released by cytotechnologists, and all abnormal Pap diagnoses (atypical or greater) are reviewed by cytopathologists. Patients were tested for HPV as follows: atypical cells of undetermined significance (ASC-US) cytological diagnosis at any age, patients over 30 years old with a negative cytological diagnosis, and previous positive HPV result at any age. HPV testing was performed on the Cobas HPV test as per New York State Department of Health guidelines for FDA
3 RAMOS RIVERA ET AL. 415 TABLE 1 Pap patients age, racial and diagnosis distribution, MMC vs ATHENA 14 TABLE 2 ATHENA 14 Pap diagnosis distribution by age group, MMC vs MMC ATHENA No. of Pts. Percentage No. of Pts. Percentage Total % % Age distribution % a a % % % % % % % % Race distribution African American % % American Indian/ Alaskan native % % Asian % % Caucasian % % Native Hawaiian/ Pacific Islander 6 0.0% % Other/missing b % % Pap diagnosis distribution NILM % % ASC-US % % ASC-H % % LSIL % % HSIL % % SCC 1 0.0% 2 0.0% AGC % % AGC, favour neoplastic % 5 0.0% EMC> % - - Unsatisfactory % - - Invalid c % AGC, atypical glandular cells; EMC>45, endometrial cells in women over 45 years of age. a Age range not examined by the ATHENA study. b Other category includes Hispanics, which is reflective of the 52.1% from the overall MMC population. c Invalid was the term in the ATHENA study used for endometrial cells older than 40 years of age, inadequate cellularity, or no sample tested. modified laboratory developed test. 15 This is a qualitative multiplex assay that detects HPV genotypes 16, 18, and other high-risk genotypes: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. While this system allows individual detection of HPV genotypes 16 and 18 it is of importance to note that all additional genotypes utilise a single detection channel and cannot be differentiated. Internal cellularity controls utilise an amplified portion of the beta globin gene. The race distribution at MMC is 32.4% (n=6638) African American, 0.3% (n=69) American Indian/ Alaskan native, 0.7% (n=131) ATHENA Age group Cytological diagnosis MMC patients (n=20 483) study patients (n=46 887) <30 ASCUS and LSIL % % ASC-H andhsil % % Total % % 30 ASCUS and LSIL % % ASC-H and HSIL % % Total % % Asian, 14.5% (n=2965) Caucasian, 0.0% (n=6) Native Hawaiian/Pacific Islander and 52.1% (n=10 674) other race. Data from the ATHENA study were culled from publically available databases and literature. 3 RESULTS At the MMC Division of Cytology, SurePath Pap tests were received from 5 October 2015, through to 30 March 2016, of patients ranging from 16 to 95 years (mean age 42 years) as shown in Table 1. Compared with the patient population in the ATHENA study, the age distributions differ somewhat in that the percentage of patients with 50 years or older is greater, and the percentage of patients with years is lower in our study population. Only 14.5% of the patients identified themselves as Caucasian at MMC, vs 83.0% of the patients in the ATHENA study. Half of the population identified themselves as Hispanic (included in the Other group) and about one-third as African American demonstrating that the MMC population is much more racially diverse compared with the ATHENA study. As shown in Table 1, the MMC population has an increased rate of gynecologic abnormality compared to ATHENA. In the ATHENA study, 90.9% of the Pap tests were diagnosed as negative for intraepithelial lesion or malignancy (NILM); in the MMC population, the NILM percentage is 83.9%. The percentages of Pap tests in all abnormal diagnostic categories are higher in our study population. Patients with a cytology diagnosis of atypical cells of undetermined significance, cannot exclude HSIL (ASC-H) or HSIL is higher in patients 30 years and older compared with the younger population. Furthermore, it is slightly higher in MMC patients (0.5%) when compared with the ATHENA study (0.3%) as seen in Table 2. Of the study patients, a total of (72.9%) underwent Cobas HPV testing. Of those tested, 3180 (21.5%) samples were positive for hrhpv. Samples tested included 1770 (12%) with a cytological diagnosis of ASC-US (reflex testing for ASCUS at MMC); the remaining 88% represented hrhpv co-testing, most commonly in patients older than 30 years with normal cytology.
4 416 RAMOS RIVERA ET AL. TABLE 3 hrhpv testing results by patient age group, MMC vs ATHENA 14 MMC patients ATHENA study patients HPV 16 HPV 18 HPV 16 positive HPV 18 Age Patient tested OHR positive positive positive Patient tested OHR positive positive < % % % 9 1.8% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % 7 0.2% Total % % % % % % % % TABLE 4 HPV results by cytology diagnosis categories a HPV genotype EMC>45 NILM ASC-US LSIL ASC-H HSIL Total % % % % % % % % 16 and OHR 1 0.3% % % % 5 8.2% 3 9.7% % 16 and <0.1% 4 0.2% % % 16, 18 and OHR % 9 0.5% 3 1.0% % % % % 8 2.7% 2 3.3% % 18 and OHR 1 0.3% % % % 2 3.3% 1 3.2% % Total 16 and/or 18 with or without OHR 6 2.0% % % % % % % OHR only % % % % % % % Negative % % % % % 1 3.2% % Grand total % % % % % % % a Failed and invalid HPV results, and glandular abnormalities were excluded (149 cases of ). Table 3 shows the distribution of positive COBAS HPV test results for HPV 16 and 18 (with or without other genotypes), and OHR genotypes only by age group. Similar to the ATHENA study, OHR genotypes are the most common type in all age groups, with the decreasing prevalence with age from 45.8% in patients under 25, to 12.8% in patients over 60 years. In all age groups, the percentage of MMC patients who test positive for OHR genotypes is higher than in the ATHENA study. The difference is most marked in patients under 30 years, likely because testing within this group is performed on samples with abnormal cytology at MMC, whereas all patients in the ATHENA study underwent HPV testing. With regard to HPV 16 and 18, the percentage of MMC patients who test positive for these HPV genotypes is slightly lower compared with ATHENA in the group <30 years old. In patients over 30 years old, the percentage of MMC patients who test positive for HPV 16 and 18 is higher than in ATHENA study, reflecting the fact that this is a high-risk population. The correlation of cytology diagnoses and Cobas HPV test results is shown in Table 4. The percentages shown are the percentage within each diagnostic category with a given HPV result. As expected, the percentage of hrhpv positive results, both overall and for individual genotypes, increases with increasing level of cytologic abnormality. HPV 16 only, for example, is present in 1.7% of cases diagnosed as NILM and increases to 19.4% in cases diagnosed as HSIL. OHR genotypes only are present in 13.7% of NILM and 64.5% (20 of 31 cases) of HSIL. Moreover, OHR genotypes were the only type identified in the one case that proved to show invasive cancer on biopsy. Of the 20 OHR only positive cases, 18 have had histological follow-up thus far, of which 12 (60%) showed HSIL or worse, including one squamous cell carcinoma (SCC). Of the HPV 16 positive cases, three out of six (50%) with histologic follow-up showed HSIL diagnosis on cytology. The numbers are small, and cyto-histological correlation may be limited by biopsy sampling error, but, based on limited data, there appears to be no marked difference between the HPV 16 and OHR genotypes in histological follow-up of cases showing HSIL on cytology. A majority of the HSIL patients had a history of prior abnormal cytology (ASC-US or greater) and or histology, which not infrequently, extended over years. Twenty patients had prior abnormality: 12 of them (60%) had OHR genotype, three had HPV 16, two had HPV 16 and OHR, and one had HPV 18 and OHR. One patient had a prior negative history and the remaining patients either had no prior Pap tests performed at MMC or had a gap in the follow-up of
5 RAMOS RIVERA ET AL. 417 at least 5 years preceding the current Pap. This appears to be true regardless of HPV type. 4 CONCLUSIONS The ATHENA trial provided early data which ultimately led to the FDA approval of the Roche COBAS HPV assay. It additionally demonstrated genotypic data from a large multicentre cohort from the United States. While the undertaking of the trial was of enormous proportions, analysis of the study populations revealed that concerns regarding the homogeneity of the population tested may have an impact on their results. With respect to race 83% of the ATHENA population identified as Caucasian. This is a remarkable contrast to the population at our institution where only a small proportion of the patient population is categorised as such. There is strong data suggesting ethnic and regional variations in HPV infection rates as well as genotypes. The population in our study mirrors more directly the population of the county of the Bronx. This diverse population presents with its own distinct challenges in providing health care to several underserved communities. Our results indicate that in nearly every age group the positivity of OHR HPV genotypes is greater in our diverse population vs the ATHENA group; however, the proportion of HPV 16 and 18 are not significantly different. This may indicate that while the burden of HPV 16 and 18 are similar in both populations, our more diverse population may demonstrate a wider variety of viral genotypes. Additionally, no conclusion can be drawn regarding viral genotypes not assayed by the COBAS HPV test. Given the geographic, ethnic and socioeconomic variation of HPV types, it is not without merit to suggest that this diverse population may harbour additional high-risk types, but are simply not detected by the assay. This consideration may very well become more of a concern as vaccination programmes directed toward HPV 16 and 18, may shift the disease burden away from these viral genotypes. The MMC study population is very different from the ATHENA study group. The MMC population closely resembled the overall Bronx population, where Hispanics and African Americans compose more than 80% of the population. In the ATHENA population, 83% were Caucasians. This substantial difference in population diversity is reflected in the contrasting results between both groups. The data from our study population revealed that OHR genotypes are the most common present in all age groups and are associated with the majority of HSILs. It also was associated with the only invasive cancer case in the study, which seems contrary to prior reports that HPV 16 and 18 account for a majority of invasive cancers. Interestingly, the prevalence of hrhpv within every age category is higher in our study population compared with the ATHENA study population. This unexpected finding highlights that the current ASCCP guidelines do not take into consideration the unfavourable outcomes OHR genotypes have and their risk of developing highgrade squamous lesions. The present results suggest that OHR genotypes should be treated the same way as HPV genotypes 16 and 18. Based on these results, we recommend expanding hrhpv testing for cervical cancer screening to include OHR genotypes and warrant the same care and follow-up currently applied for HPV genotypes 16 and 18. Given the racial and ethnic diversity of the Bronx population, and in light of prior studies demonstrating regional differences in prevalent genotypes, further genotyping of MMC patients with abnormal cervical cytology may reveal additional genotypes that should be targeted for developing vaccines and diagnostic technology. Increased attention may need to be placed on prevention through extending coverage of HPV vaccines to include other hrhpv genotypes as we begin to understand the nuances of HPV genotype distributions among varying populations. While this study identifies a greater prevalence of other high-risk HPV types in a diverse population, our data raise additional questions that require further studies. What other genotypes are causative in disease progression other than the ones included in the diagnosis platform? What is the natural history of the OHR genotypes? What is the role of co-infection among OHR genotypes and other sexually transmitted infections? These questions will require additional study as we begin to expand our understanding of HPVrelated cervical disease. Prospective studies within the diverse population in the Bronx will further allow for elucidation of some of these questions. REFERENCES 1. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202: Clifford G, Franceschi S, Diaz M, Mu~noz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(Suppl 3): Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human Papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97: Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008;18: Rao A, Young S, Erlich H, et al. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol May;51: Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. CA Cancer J Clin. 2012;62: Massad LS, Einstein MH, Huh WK, et al updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(Suppl 1): Awua AK, Sackey ST, Osei YD, Asmah RH, Wiredu EK. Prevalence of human papillomavirus genotypes among women with cervical cancer in Ghana. Infect Agent Cancer. 2016;11:4.
6 418 RAMOS RIVERA ET AL. 9. Robison K, Hosmer J, Murray A, et al. Prevalence of HPV and type distribution in Southeast Asian women residing in Rhode Island. Austin J Obstet Gynecol. 2014;1: Ye F, Chan N, Feng T, et al. High prevalence of HPV59 in cytologically abnormal cervical samples. Exp Mol Pathol. 2015;99: Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1: Population Estimates, July 1, 2015, (V2015). Census.gov. N.p., Web Accessed June 30, College of American Pathologists (CAP). All Common Checklist, Cytopathology Checklist. July 28, Available at: p.org. Accessed November 16, Wright TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206: Naeem RC, Goldstein DY, Ramos Rivera G, et al. SurePath specimens versus ThinPrep specimen types on the COBAS 4800 platform: high-risk HPV status and cytology correlation in an ethnically diverse Bronx population. Lab Med. 2017; [Epub ahead of print]. How to cite this article: Ramos Rivera G, Khader SN, Lajara S, et al. The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population. Cytopathology. 2017;28:
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationOriginal Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD;
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More information(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD
More informationHPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION
HPV Vaccine FAST FACTS: Payer & Reimbursement Strategies Medicaid: Many state Medicaid programs cover the HPV vaccine, though this coverage varies by state. Information on coverage can be found through
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationHPV Primary Screening in the United States
IFCPC 15th World Congress May 2014, London, UK. HPV Primary Screening in the United States E.J. Mayeaux, Jr., M.D. Professor and Chairman Department of Family and Preventive Medicine Professor of Obstetrics
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationEmerging Challenges in Primary Care. Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing
Emerging Challenges in Primary Care Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationSince the 1960s, colposcopy of the cervix with
Original Research Relevance of Random Biopsy at the Transformation Zone When Colposcopy Is Negative Warner K. Huh, MD, Mario Sideri, MD, Mark Stoler, MD, Guili Zhang, PhD, Robert Feldman, MD, and Catherine
More informationASCCP Guideline Changes and Management of the Abnormal Pap Test Accurately Targeting Intervention
ASCCP Guideline Changes and Management of the Abnormal Pap Test Accurately Targeting Intervention Beryl Manning-Geist MD a,c, Allison Vitonis Sc. M. a, Michelle Davis MD a,b, Sarah Feldman MD MPH a,b a
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationOriginal Articles. Squamous Cell Carcinoma of the Cervix. A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice
Original Articles Squamous Cell Carcinoma of the Cervix A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice Ross A. Miller, MD; Lindsay L. Waters, MD; Dina R. Mody, MD; Kimberlee
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More information1/12/2016. I do not engage in any lucrative deals that require disclosure.
I do not engage in any lucrative deals that require disclosure. Sabrina Hofmeister, DO Assistant Professor Columbia St. Mary s Family Medicine Residency Program MCW Department of Family and Community Medicine
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationClinical Performance of Roche COBAS 4800 HPV Test
JCM Accepts, published online ahead of print on 9 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00883-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5 6 Clinical
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years
Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages 21-39 years Michelle I. Silver, PhD, ScM Cancer Prevention Fellow National Cancer Institute Division of Cancer
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationCervical Cancer Screening Guidelines Update
Frontier AIDS Education and Training Center Cervical Cancer Screening Guidelines Update Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics Frontier AETC, Medical Program Director
More informationThe new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
More informationGYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
More informationCopyright information:
Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory Zhengyu Zeng, Guangzhou Kingmed Diagnost Huaitao
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationCan human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol. 2016 Nov;27(6):e56 pissn 2005-0380 eissn 2005-0399 Original Article Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification? Yeoun Eun
More informationThe Biology of HPV Infection and Cervical Cancer
The Biology of HPV Infection and Cervical Cancer Kaitlin Sundling, M.D., Ph.D. Clinical Instructor Faculty Director, Cytotechnology Program Wisconsin State Laboratory of Hygiene and University of Wisconsin
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationNo Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016
Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,
More informationQuarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology
Legacy LabAdvisor Quarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology Edition 3 Inside this issue New Testing Developments.... 2 Test Algorithm...
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationManitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006
anitoba Cervical Cancer Screening Program Operations & Statistical Report 2005 and 2006 1 MCCSP 2005-2006 Report ANITOBA CERVICAL CANCER SCREENING PROGRAM 2005 and 2006 Operations & Statistical Report
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationDetecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationHPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital
HPV Primary Screening Update Prof. Vu Ba Quyet Director of NO&G hospital 1 Who can we not worry about? 2 Key questions Who should be screened? Starting age? Ending age? How often? How to manage results?
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationOctober 9, Dear Ms. Chowdhury:
October 9, 2017 Joya Chowdhury, MPH Senior Coordinator, USPSTF Department of Health and Human Services Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Room 06E65A
More information9/19/17. Emerging Challenges in Primary Care: Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing. Faculty.
Emerging Challenges in Primary Care: 2017 Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause
More informationVaginal Neoplasia-A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results
Vaginal Neoplasia-A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results Michelle J. Khan, MD, MPH Assistant Professor Department of Obstetrics and Gynecology
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationEvidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR
Evidence-based treatment of a positive HPV DNA test Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR HPV DNA testing Indications 1. Triage after cytology with ASCUS/LSIL
More informationRecommendation Summary U S. Prevention Statement Task Force for HPV (USPSTF)
Recommendation Summary U S. Prevention Statement Task Force for HPV (USPSTF) Population Recommendation Grade (What's This?) Women ages 21 to 65 years The USPSTF recommends screening for cervical cancer
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationComparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Ming Guo
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/comparing-liquid-based-cytology-methodsdetection-cervical-cancer-perspectives-dr-ming-guo/7469/
More informationDisclosures. Goal of Cervical Cancer Screening. Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing
Disclosures Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing Consultant and Speaker: Hologic Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationName of Policy: Speculoscopy
Name of Policy: Speculoscopy Policy #: 095 Latest Review Date: September 2011 Category: Medicine/OB Gyn Policy Grade: C Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More information